@CTBio

Advocate for biotech/biopharma research & development as Sr Counsel/Executive Director-CT Bioscience Growth Council, Chair-WeWorkForHealthCT

 Hartford, CT
cbia.com/bioscience
Joined November 2014
  • Tweets945
  • Following323
  • Followers276
8Media
Include

Only show posts containing:

Exclude

Hide posts containing:

Time range
-
Minimum likes
Amgen's FGFR2b-targeting cancer candidate boosts overall survival in phase 3 fiercebiotech.com/biotech/am…

Amgen's FGFR2b-targeting cancer candidate boosts overall survival in phase 3

Amgen’s investigational monoclonal antibody paired with chemotherapy significantly improved overall survival for patients in a phase 3 stomach cancer trial compared to chemotherapy alone, according |...

fiercebiotech.com
34
J&J @JNJInnovation ties early-stage lymphoma CAR-T to 100% response rate in 10 patients fiercebiotech.com/biotech/jj…

J&J ties early-stage lymphoma CAR-T to 100% response rate in 10 patients

Johnson & Johnson is providing a first look at

fiercebiotech.com
22
Paul Pescatello retweeted
CBIA@CBIANews3 Jun 2025
“We’ve got to tell the story about a difference that we’re making in people’s lives,” @GovNedLamont said during a visit to CBIA member @ViiVUS honoring the company’s growth and breakthroughs in HIV treatment. ctinsider.com/business/artic… #research #innovation #Connecticut

Connecticut biotech company honored for advancing HIV prevention drugs while adding jobs

"It’s just worth reminding people every day that we’re making a difference, and it’s working, and we’re saving lives,” Gov. Ned Lamont said.

ctinsider.com
1
106
ASCO: Pfizer, chasing full approval conversion for Braftovi combo, touts 'unprecedented' survival win fiercepharma.com/pharma/asco…

ASCO: Pfizer, chasing full approval conversion for Braftovi combo, touts 'unprecedented' survival...

Pfizer isn’t stopping to smell the roses on its speed run to secure a full FDA approval for its Braftovi combination therapy. | Pfizer's Braftovi, combined with Eli Lilly's Erbitux and chemo, won an...

fiercepharma.com
1
14
Well-deserved recognition for Branford-based @ViiVUS, honored by @GovNedLamont for its global efforts to end HIV/AIDS. ViiV's cutting-edge research is at the forefront in the battle to end HIV, helping create 17 medications used by thousands of people across the globe.
2
2
172
Paul Pescatello retweeted
CBIA@CBIANews30 May 2025
“#Innovation isn’t just technology, robots, and hardware,” @ChrisDipentima tells @WTNH's @MikeCerulliCT and @thevoiceofct's Melissa Sheketoff on MADE Conversations about how businesses innovate in areas like employee #engagement and #workplace culture. bit.ly/4mIPJqI
2
1
183
Sanofi to acquire Vigil Neuroscience in $470 million deal to boost neurological pipeline reuters.com/markets/deals/sa…

Sanofi to acquire Vigil Neuroscience in $470 million deal to boost neurological pipeline

Sanofi will acquire Vigil Neuroscience , a clinical-stage biotech company in a $470 million deal, the companies said on Thursday, as the French drugmaker seeks to boost its neurological pipeline...

reuters.com
9
Paul Pescatello retweeted
BioSpace@biospace5 May 2025
The @US_FDA accepted @novonordisk's NDA for an oral formulation of Wegovy. The agency is expected to release its verdict on the drug in the fourth quarter of this year. #FDA #GLP1 #wegovy #biospace hubs.li/Q03l1wT70

Novo’s Wegovy Inches Closer to Becoming First FDA-Approved GLP-1 Weight-Loss Pill

The FDA accepted Novo Nordisk's NDA for an oral formulation of Wegovy. The agency is expected to release its verdict on the drug in the fourth quarter of this year.

biospace.com
1
2
382
Health Rounds: @boehringerus drug delivers 'unprecedented' result in lung cancer study msn.com/en-us/health/other/h…
12
hartfordbusiness.com/article…

CT Innovations sharpens healthcare focus in 3Q investments

Connecticut Innovations, the state’s venture capital arm, has announced it invested approximately $7.4 million in 19 companies and venture funds during the third quarter of its fiscal year. CI says...

hartfordbusiness.com
9
Medtronic sends Hugo robot in for FDA review with urologic study success fiercebiotech.com/medtech/me…

Medtronic sends Hugo robot in for FDA review with urologic study success

Medtronic confirmed that its Hugo surgical robot system has been submitted to the FDA for review, alongside the successful completion of a large clinical trial evaluating its performance | According...

fiercebiotech.com
22
Paul Pescatello retweeted
Pfizer Inc.
@pfizer16 Apr 2025
🎙️Out now! The bonus episodes of Science Will Win Season 4 recorded at SXSW are live! Hear how digital tools are empowering patients & how teamwork is key in the fight to out do cancer. Tune in on your favorite podcast app! 🎧 on.pfizer.com/42g1QmR
8
3
10
3,838
Boehringer Ingelheim, Cue Biopharma Partner to Commercialize Therapy for Immune Diseases contractpharma.com/breaking-…

Boehringer Ingelheim, Cue Biopharma Partner to Commercialize Therapy for Immune Diseases

Boehringer Ingelheim and Cue Biopharma Inc. have joined forces to develop and commercialize Cue Biopharma’s CUE-501 product candidate.

contractpharma.com
20
Paul Pescatello retweeted
Arvinas
@ArvinasInc4 Apr 2025
#NEWS:Arvinas Presents First-in-Human Data for Investigational Oral novel PROTAC LRRK2 Degrader Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation. Read More: bit.ly/4hXSctC
4
6
1,116
AstraZeneca’s Imfinzi regimen approved by FDA to treat bladder cancer dlvr.it/TJtJPq #News #Regulatory #AstraZeneca

AstraZeneca’s Imfinzi regimen approved by FDA to treat bladder cancer - PMLiVE

Around half of patients who undergo bladder removal surgery experience disease recurrence

pmlive.com
1
122
‘A significant milestone’: First US patients receive doses of new PET radiotracer for CAD cardiovascularbusiness.com/t…

‘A significant milestone’: First US patients receive doses of new PET radiotracer for CAD

Back in September, the FDA approved GE HealthCare’s new PET radiotracer, flurpiridaz F-18, for patients with known or suspected CAD. It is seen by many in the industry as a major step forward in...

cardiovascularbusiness.com
2
44
FDA signs off on Sanofi's insulin biosimilar, the first for Novo Nordisk's rapid-acting NovoLog fiercepharma.com/pharma/fda-…

FDA signs off on Sanofi's insulin biosimilar, the first for Novo Nordisk's rapid-acting NovoLog

More than three years after approving two biosimilars referencing Sanofi’s long-acting insulin Lantus, the FDA has signed off on a rapid-acting insulin biosimilar for the first time. | The FDA has...

fiercepharma.com
31
Paul Pescatello retweeted
CBIA@CBIANews24 Feb 2025
“We’ve really hit our stride over the last couple of years in terms of new companies being born out of academic labs, and otherwise getting funding and starting in Connecticut,” CBIA's @CTBio tells @HartfordBiz about #Connecticut’s #bioscience industry. hartfordbusiness.com/article…

Despite setbacks, investors remain bullish on CT’s bioscience sector, but changes in Washington...

The state’s bioscience sector is a lot like that box of chocolates in the film “Forrest Gump” — you never know what you’re going to get.Several state-based companies have recently […]

hartfordbusiness.com
1
1
85
Paul Pescatello retweeted
CBIA@CBIANews25 Feb 2025
CBIA Bioscience Growth Council’s @CTBio joined patients, advocates, policymakers, and industry leaders to highlight #RareDiseaseDay2025—raising awareness about these life-changing conditions and the #research and #innovation underway to improve the lives of patients and families.
2
1
85
GSK’s five-in-one meningococcal vaccine Penmenvy granted FDA approval dlvr.it/TJ1njL #News #Regulatory #FDA

GSK’s five-in-one meningococcal vaccine Penmenvy granted FDA approval - PMLiVE

It is hoped that the combination vaccine will simplify delivery and lead to higher uptake

pmlive.com
2
109
Load more